Sponsors

Lead Sponsor

Bayer

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•A diagnosis of nAMD
•Patient aged ≥50 years
•Patients for whom the decision to initiate treatment with intravitreal (IVT) aflibercept 8 mg according to a local product information was made as part of routine clinical practice
•Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws)
•A diagnosis of DME
•Patient aged ≥18 years (or country's legal age of adulthood if the legal age is \>18 years) with type 1 or type 2 diabetes mellitus
•Patients for whom the decision to initiate treatment with IVT aflibercept 8 mg according to a local product information was made as part of routine clinical practice
•Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws)

Exclusion Criteria

•Participation in an investigational program with interventions outside of clinical routine practice
•Contraindications as listed in the local intravitreal aflibercept 8 mg local product information
•Extra/periocular infection or inflammation in either eye at time of first injection
•Patient receiving other intravitreal treatments other than aflibercept in the fellow eye
•Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days
•Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months
•Fluocinolone implant in the study eye within the last 3 years
•Dexamethasone implant in the study eye within the last 6 months
•Any concurrent drug releasing implant in the study eye
•Participation in an investigational program with interventions outside of clinical routine practice
•Contraindications as listed in the intravitreal aflibercept 8 mg local product information
•Extra/periocular infection or inflammation in either eye at time of first injection
•Patient receiving other intravitreal treatments other than aflibercept in the fellow eye
•Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8 mg local product information
•Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days
•Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months
•Fluocinolone implant in the study eye within the last 3 years
•Dexamethasone implant in the study eye within the last 6 months
•Any concurrent drug releasing implant in the study eye

Related studies

RECRUITING

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

NCT07308639 · Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)

RECRUITINGNA

In-person and Telehealth Visual Rehabilitation for Children With Low Vision

NCT06701617 · Visual Rehabilitation, Oddball Design, and more

RECRUITING

Validation of a Parental Questionnaire for Screening Children for Neurovisual Disorders

NCT06997354 · Children Suffering From Cortical Visual Impairment

Active Not Recruiting

A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema

NCT06929143 · Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)

Active Not RecruitingPhase 2

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT04514653 · Neovascular Age-Related Macular Degeneration (nAMD)

View all related studies →

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

In-person and Telehealth Visual Rehabilitation for Children With Low Vision

Validation of a Parental Questionnaire for Screening Children for Neurovisual Disorders

A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Trial snapshot

Condition

Locations shown

For caregivers